Felodipine‐induced gingival hyperplasia: a clinical and histologic study

There is an increasing number of medications associated with gingival overgrowth. These medications are used to treat a number of common conditions in the Australian population and as such dentists can expect to manage a number of patients with medication-related gingival overgrowth. This review highlights the clinical features and management of the common overgrowths associated with anticonvulsants, immunosuppressants and the calcium channel blockers.

show abstract

“…74,75 In both cases the gingival overgrowth began soon after the patients commenced felodipine (Fig. 2f).…”

Section: Felodipinementioning

confidence: 92%

A clinical review of drug‐induced gingival overgrowths

Marshall

Bartold

1999

Australian Dental Journal

129

139

View full text Add to dashboard Cite

show abstract

“…13 As for Verapamil 14 and amlodipine, the prevalence was significantly lower (4.2% and 3.3%, respectively) than that of nifedipine. 8 Since then, numerous reports have associated gingival enlargement with the newer generation of CCBs, such as felodipine, 15 nicardipine, 16 manidipine 17 and diltiazem. 18 …”

Section: Gingival Enlargementmentioning

confidence: 99%

Calcium channel blocker-induced gingival enlargement

Livada

Shiloah

2013

J Hum Hypertens

View full text Add to dashboard Cite

Despite the popularity and wide acceptance of the calcium channel blockers (CCBs) by the medical community, their oral impact is rarely recognized or discussed. CCBs, as a group, have been frequently implicated as an etiologic factor for a common oral condition seen among patients seeking dental care: drug-induced gingival enlargement or overgrowth. This enlargement can be localized or generalized, and can range from mild to extremely severe, affecting patient's appearance and function. Treatment options for these patients include cessation of the offending drug and substitution with another class of antihypertensive medication to prevent recurrence of the lesions. In addition, depending on the severity of the gingival overgrowth, nonsurgical and surgical periodontal therapy may be required. The overall objective of this article is to review the etiology and known risk factors of these lesions, their clinical manifestations and periodontal management.

show abstract

“…44,45 Gingival enlargement in patients treated with this drug was originally reported in 1984 by Lederman et al 19 and Ramon et al 21 More recently, gingival enlargement also has been described in patients treated with other dihydropyridines, such as nitrendi-pine, nicardipine, felodipine, and amlodipine. [46][47][48][49][50][51][52] Because the majority of studies are based on series of cases with a small number of patients, the true prevalence of nifedipine-induced gingival enlargement is unknown. 17,27,[53][54][55][56] On the other hand, predictors of gingival enlargement in patients treated with nifedipine have not been previously assessed.…”

mentioning

confidence: 99%

Prevalence and Risk of Gingival Enlargement in Patients Treated With Nifedipine

Miranda

Brunet

Roset

et al. 2001

Journal of Periodontology

View full text Add to dashboard Cite

Background: Gingival enlargement is a known side effect of nifedipine use. This study was conducted to determine the prevalence and risk factors for gingival enlargement in nifedipinetreated patients.Methods: A cross-sectional study was conducted in a primary care center. Data from 65 patients taking nifedipine were compared with 147 controls who had never received the drug. All patients were examined for the presence of gingival enlargement using 2 different indices: vertical gingival overgrowth index (GO) in 6 points around each tooth, and horizontal MB index in the interdental area. Gingival index, plaque index, and probing depth were also evaluated.Results: The prevalence of gingival enlargement was significantly higher in nifedipine-treated cases than in controls (GO index, 33.8% versus 4.1%; MB index, 50.8% versus 7.5%, respectively). Higher gingival and plaque indices were observed in patients taking nifedipine. Among the possible risk factors, only the gingival index showed a significant association with gingival enlargement. The risk (odds ratio [OR]) of gingival enlargement associated with nifedipine therapy was 10.6 (3.8-29.1) for the GO index and 14.4 (6-34.6) for the MB index. Gingival index-adjusted ORs were 9.6 (3.3-28.1) and 9.7 (3.9-23.3), respectively. In the subset of high nifedipine exposure patients, the odds ratio for gingival enlargement increased to 17.4 (5.3-56.3) for the 3) for the MB index. The concordance between GO and MB indices showed a kappa value of 0.689 in controls and 0.642 in patients treated with nifedipine.Conclusions: Patients taking nifedipine are at high risk for gingival enlargement, and gingivitis acts as a predisposing factor. J Periodontol 2001;72:605-611.

show abstract

Felodipine‐induced gingival hyperplasia: a clinical and histologic study

Cited by 48 publications

References 33 publications

A clinical review of drug‐induced gingival overgrowths

A clinical review of drug‐induced gingival overgrowths

Calcium channel blocker-induced gingival enlargement

Prevalence and Risk of Gingival Enlargement in Patients Treated With Nifedipine

Contact Info

Product

Resources

About